OverviewSuggest Edit

Galapagos is a biotechnology company. It specializes in the development and commercialization of small molecule medicines. The Company is engaged in pre-clinical studies and discovery programs in inflammation, fibrosis and other indications. 
TypePublic
Founded1999
HQMechelen, BE
Websiteglpg.com
Employee Ratings3.5

Latest Updates

Employees (est.) (Jul 2021)1,328(-10%)
Job Openings31
Revenue (FY, 2020)€478.1 M(-43%)
Share Price (Jul 2021)€51.2(+2%)
Cybersecurity ratingBMore

Key People/Management at Galapagos

Onno van de Stolpe

Onno van de Stolpe

CEO
Howard Rowe

Howard Rowe

Non-Executive Independent Director
Piet Wigerinck

Piet Wigerinck

Chief Scientific Officer
Mary Kerr

Mary Kerr

Non-Executive Independent Director
Bart Filius

Bart Filius

Chief Operating Officer & Chief Financial Officer
Peter Guenter

Peter Guenter

Non-Executive Independent Director
Show more

Galapagos Office Locations

Galapagos has offices in Mechelen, Waltham, Zagreb, Romainville and in 2 other locations
Mechelen, BE (HQ)
Generaal de Wittelaan L11, A3
Zagreb, HR
prilaz baruna Filipovića 29
Romainville, FR
102 Avenue Gaston Roussel
Leiden, NL
Zernikedreef 16
Basel, CH
Aeschengraben 20
Waltham, MA, US
230 CityPoint, 230 3rd Ave
Show all (6)

Galapagos Financials and Metrics

Galapagos Revenue

Galapagos's revenue was reported to be €478.05 m in FY, 2020
EUR

Revenue (FY, 2020)

478.1m

Net income (FY, 2020)

(305.4m)

EBIT (FY, 2020)

(178.6m)

Market capitalization (21-Jul-2021)

3.4b

Closing stock price (21-Jul-2021)

51.2

Cash (31-Dec-2019)

1.9b
Galapagos's current market capitalization is €3.4 b.
EURFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

60.6m151.6m155.9m288.8m845.0m478.1m

Revenue growth, %

150%3%

Sales and marketing expense

1.2m1.8m2.8m

General and administrative expense

19.1m21.7m24.4m
EURFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

340.3m973.2m1.2b320.5m1.9b

Accounts Receivable

3.9m9.7m28.0m

Inventories

325.0k300.0k279.0k

Current Assets

374.5m1.0b1.2b1.3b5.9b
EURFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(118.4m)54.0m(115.7m)(305.4m)

Depreciation and Amortization

3.4m4.2m4.3m

Inventories

(44.0k)25.0k22.0k

Accounts Payable

(39.5m)2.1m14.8m
EURFY, 2015

Revenue/Employee

139.3k

Financial Leverage

1.2 x
Show all financial metrics

Galapagos Revenue Breakdown

Embed Graph

Galapagos revenue breakdown by business segment: 91.3% from R&D and 8.7% from Fee-for-services

Galapagos Cybersecurity Score

Cybersecurity ratingPremium dataset

B

81/100

SecurityScorecard logo

Galapagos Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Galapagos Online and Social Media Presence

Embed Graph

Galapagos News and Updates

Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation

Mechelen, Belgium; 14 July 2021; 22.01 CET; regulated information – Galapagos NV (Euronext & Nasdaq: GLPG) reports topline results with GLPG3970 in three patient studies. GLPG3970, the first product candidate from a broad portfolio of SIK inhibitor compounds, provides clinical data supporting th…

Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study

Mechelen, Belgium; 14 July 2021; 22.01 CET; regulated information - Galapagos NV (Euronext & Nasdaq: GLPG) reports positive topline results with tyrosine kinase 2 (TYK2) inhibitor GLPG3667 in a Phase 1b study in psoriasis patients. GLPG3667 was discovered by Galapagos.

Galapagos announces new data supporting rapid symptom improvement and sustained steroid-free remission with filgotinib in patients with Ulcerative Colitis

New post-hoc analyses of data from SELECTION Phase 3 program presented at European Crohn’s and Colitis Organisation (ECCO) virtual congress

Celebrity Flora Fulfills Long-Awaited Bucket-List Moments for Wanderlust Travelers as Celebrity Cruises Returns to the Galapagos Islands

MIAMI, July 4, 2021 /PRNewswire/ -- Travelers who have waited more than 15 months to experience the wonders of the world set sail today in the breath-taking Galapagos Islands aboard the luxurious, state-of-the-art mega yacht, Celebrity Flora. The first of the new-luxury brand's three...

Up to 50% Off on Select Hurtigruten Expedition Cruises: Antarctica, Alaska, Galapagos, Iceland, and Norway

Numerous bucket list destinations on sale during the Canada Day flash sale SEATTLE, July 1, 2021 /PRNewswire/ -- Hurtigruten Expeditions, the world leader in exploration travel, is offering almost all its 2021-22 itineraries at an incredible discount of up to 50% off from July 1 to July 8...

Galapagos announces departure of CSO Piet Wigerinck later this year

Mechelen, Belgium; 22 June 2021, 22.01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announces the departure of Dr. Piet Wigerinck later this year.
Show more

Galapagos Frequently Asked Questions

  • When was Galapagos founded?

    Galapagos was founded in 1999.

  • Who are Galapagos key executives?

    Galapagos's key executives are Onno van de Stolpe, Howard Rowe and Piet Wigerinck.

  • How many employees does Galapagos have?

    Galapagos has 1,328 employees.

  • What is Galapagos revenue?

    Latest Galapagos annual revenue is €478.1 m.

  • What is Galapagos revenue per employee?

    Latest Galapagos revenue per employee is €360 k.

  • Who are Galapagos competitors?

    Competitors of Galapagos include Roivant Sciences, Pliant Therapeutics and ANA Therapeutics.

  • Where is Galapagos headquarters?

    Galapagos headquarters is located at Generaal de Wittelaan L11, A3, Mechelen.

  • Where are Galapagos offices?

    Galapagos has offices in Mechelen, Waltham, Zagreb, Romainville and in 2 other locations.

  • How many offices does Galapagos have?

    Galapagos has 6 offices.